Publikationen

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; LICKA M EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. PMID: 32865377.

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; LICKA, M ORION-10 and ORION-11 Investigators.(2020). Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18.

Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; Licka M (MARINER Investigators). (2018). Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018 Sep20; 379(12): 1118-1127. DOI: 10.1056/NEJMoa1805090

Gibson CM1, Korjian S2, Chi G2, Daaboul Y2, Jain P2, Arbetter D2, Goldhaber SZ3, Hull R4, Hernandez AF5, Lopes RD5, Gold A6, Cohen AT7, Harrington RA8; Licka, M (APEX Investigators. (2017). Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11;6(7). DOI: 10.1161/JAHA.117.006015

Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; Licka, M (SPIRE Cardiovascular Outcome Investigators). (2017). Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med. 2017 Apr 20;376(16):1527-1539. DOI: 10.1056/NEJMoa1701488

Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; Licka M (EINSTEIN CHOICE Investigators).(2017). Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Mar 30; 376 (13): 1211-1222. DOI: 10.1056/NEJMoa1700518

Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino ,M, Jin J; Licka M (2016). Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. The Lancet. 2016 Oct 22; 388 (10055): 1995-2003.

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; Licka M (APEX Investigators). (2016). Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 Aug 11; 375 (6): 534-44. DOI: 10.1056/NEJMoa1601747

Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW; Licka M (RIVER-PCI investigators). (2016). Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Jan 9; 387 (10014): 136-45. DOI: 10.1016/S0140-6736(15)00459-6

Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ; Licka M (PALLAS investigators). (2014). Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol. 2014 Dec; 7 (6): 1019-25. DOI: 10.1161/CIRCEP.114.002046

Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S; Licka M (AVERROES Steering Committee and Investigators). (2012). Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012 Mar; 11 (3): 225-31.

Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; Licka M (PALLAS Investigators). (2011). Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15; 365 (24): 2268-76.

Licka M, Jahn L, Kelemen K, Voss F, Trappe K, Becker R, Bikou O, Hauck M, Koch M, Katus HA, Bauer A. (2011). Is the determination of the defibrillation threshold in patients with an implantable cardioverter-defibrillator still required? Herzschrittmacherther Elektrophysiol. 2011 Dec; 22(4): 209-13.

Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; Licka M (Averroes Steering Committee and Investigators). (2011). Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3; 364 (9): 806-17.

Bikou O*, Licka M*, Kathoefer S, Katus HA, Bauer A. Cost savings and safety of ICD remote control by telephone: a prospective, observational study. J Telemed Telecare. 2010; 16 (7): 403-8. (*: equally contributed).

Thomas D, Khalil M, Alter M, Schweizer PA, Karle CA, Wimmer AB, Licka M, Katus HA, Koenen M, Ulmer HE, Zehelein J. (2010). Biophysical characterization of KCNQ1 P320 mutations linked to long QT syndrome 1. J Mol Cell Cardiol. 2010 Jan; 48 (1):230-7.

Simon T, Becker R, Voss F, Bikoue O, Hauck M, Licka M, Katus HA, Bauer A. (2008). Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events. Clin Res Cardiol. 2008 May; 97 (5): 306-9.

Thomas D, Wimmer AB, Karle CA , Licka M, Alter M, Khalil M, Ulmer HE, Kathöfer S, Kiehn J, Katus HA, Schoels W, Koenen M, Zehelein J. (2005). Dominant-negative I(Ks) suppression by KCNQ1-deltaF339 potassium channels linked to Romano-Ward syndrome. Cardiovasc Res. 2005 Aug 15; 67 (3): 487-97.

Zehelein J, Thomas D, Khalil M, Wimmer AB, Koenen M, Licka M, Wu K, Kiehn J, Brockmeier K, Kreye VA, Karle CA, Katus HA, Ulmer HE, Schoels W. (2004). Identification and characterisation of a novel KCNQ1 mutation in a family with Romano-Ward syndrome. Biochem Biophys Acta. 2004 Nov 5; 1690 (3): 185-92.

Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kübler W. (2002). Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart. 2002 Jun; 87 (6): 520-4.

Bauer A, Schnabel PA, Schreiner KD, Becker R, Voss F, Kraft P, Senges J, Licka M, Kübler W, Schoels W. (2001). Effects of propafenone on anisotropic conduction properties within the three-dimensional structure of the canine ventricular wall. Basic Res Cardiol. 2001 Apr; 96 (2): 175-83.

Berthold F, SahinK, Hero B, Christiansen H, Gehring M, Harms D, Horz S, Lampert F, Schwab M, Terpe J. (1997). The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur J Cancer.1997 Oct; 33 (12): 2092-7

Gehring M, Berthold F, Edler L, Schwab M, Amler LC. (1995). The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res. 1995 Nov 15; 55 (22): 5366-9.

Corvi R, Amler LC, Savelyeva L, Gehring, M, Schwab M. (1994). MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci U S A. 1994 Jun 7; 91 (12): 5523-7.

Gehring M, Berthold F, Schwab M, Amler L. (1994). Genetic stability of microsatellites in human neuroblastomas. Int J Oncol. 1994 May;4 (5): 1043-5.

Kleihues P, Ohgaki H, Eibl RH, Reichel MB, Mariani L, Gehring M, Petersen I, Höll T, von Deimling A, Wiestler OD, et al. (1994). Type and frequency of p53 mutations in tumors of the nervous system and its coverings. Recent Results Cancer Res. 1994; 135: 25-31.

Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, Petersen I, Höll T, Wiestler OD, Kleihues P. (1993). Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog.1993; 8 (2): 74-80

Gehring M, Haag D., Goerttler K., Schwab M. (1993). Combined analysis of prognostic parameters in neuroblastoma. Clinical Chemistry and Enzymology Communications. 1993; 5 (4-6): 213-218

Takayama H, Suzuki T, , Mugishima H, Fujisawa T, Ookuni M, Schwab M, Gehring M, Nakamura Y, Sugimura T, Terada M, et al. (1992). Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene. 1992 Jun; 7 (6): 1185-9.